Triple therapy in type 2 diabetes; A systematic review and network meta-analysis

PeerJ

Volumn 2015, Issue 12, 2015, Pages

  Downes, Martin J ^a   Bettington, Emilie K ^a   Gunton, Jenny E ^b   Turkstra, Erika ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti diabetic medication; Glycated haemoglobin; Network meta analysis; Oral antidiabetic drugs; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ARTICLE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SYSTEMATIC REVIEW;

EID: 84951136886     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.1461     Document Type: Article

References (45)

1. American Diabetes Association. 2014. Standards of medical care in diabetes-2014. Diabetes Care 37(Suppl 1):S14-S80 DOI 10.2337/dc14-S014.
2. Australian Government DoH. 2010. Public Summary Document for Vildagliptin, tablet, 50 mg, Galvus®-March 2010. Canberra: Pharmaceutical Evaluation Branch, Department of Health. Available at http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2010-03/pbac-psd-Vildagliptin-mar10 (accessed 30 April 2015).
3. Australian Government DoH. 2013. Request for quotation for the provision of a report on the comparative safety and effectiveness of type 2 diabetes medicines. Canberra: Pharmaceutical Evaluation Branch, Department of Health. (04/30/2015). RFQ No. 067/1314.
4. Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB. 2011. Oral diabetes medications for adults with type 2 diabetes: an update. Comparative effectiveness review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Agency for Healthcare Research and Quality, Rockville. Available at www.effectivehealthcare.ahrq.gov/reports/final.cfm.
5. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLogMix-vs.-Exenatide Study G. 2009. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25(1):65-75 DOI 10.1185/03007990802597951.
6. Berhan A, Barker A. 2013. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 13(1):58 DOI 10.1186/1472-6823-13-58.
7. Bosi E, Ellis GC, Wilson CA, Fleck PR. 2011. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obesity and Metabolism 13(12):1088-1096 DOI 10.1111/j.1463-1326.2011.01463.x.
8. Canadian Agency for Drugs and Technologies in Health. 2013. Optimal use recommendations for second and third-line therapy for patients with type 2 diabetes. CADTH optimal use report; vol.3, no. 1d. Canadian Agency for Drugs and Technologies in Health, Ottawa. Available at https://www.cadth.ca/media/pdf/OP0512DiabetesRecsReport2nd3rd-linee.pdf (accessed 29 November 2015).
9. CDER (Center for Drug Evaluation and Research). 2008. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Available at http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf (accessed 30 April 2015).
10. CHMP (Committee forMedicinal Products for Human Use). 2011. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Available at http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2012/06/WC500129256.pdf (accessed 30 April 2015).
11. Cohen RM, Haggerty S, Herman WH. 2010. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? Journal of Clinical Endocrinology and Metabolism 95(12):5203-5206 DOI 10.1210/jc.2010-2352.
12. Dailey 3rd GE, Noor MA, Park JS, Bruce S, Fiedorek FT. 2004. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. The American Journal of Medicine 116(4):223-229 DOI 10.1016/j.amjmed.2003.07.022.
13. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31-40 DOI 10.1016/S0140-6736(11)60679-X.
14. Deacon CF. 2011. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 13(1):7-18 DOI 10.1111/j.1463-1326.2010.01306.x.
15. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. 2012. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 97(5):1615-1622 DOI 10.1210/jc.2011-2243.
16. Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P. 2013. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and beta-cell function: the triple oral therapy. Diabetic Medicine 30(7):846-854 DOI 10.1111/dme.12158.
17. Follmann D, Elliott P, Suh I, Cutler J. 1992. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 45(7):769-773 DOI 10.1016/0895-4356(92)90054-Q.
18. Gunton JE, Cheung NW, Davis TME, Zoungas S, Colagiuri S. 2014. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Medical Journal of Australia 201(11):650-653 DOI 10.5694/mja14.01187.
19. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. 2005. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 143(8):559-569 DOI 10.7326/0003-4819-143-8-200510180-00006.
20. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity and Metabolism 9:733-745 DOI 10.1111/j.1463-1326.2007.00744.x.
21. Higgins J, Altman D. 2011. Chapter 8: assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 510. Oxford: Cochrane Collaboration. (updated March 2011).
22. Higgins J, Green S. 2011. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Oxford: Cochrane Collaboration.
23. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. 2012. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 3(2):98-110 DOI 10.1002/jrsm.1044.
24. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. 2015. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140-149 DOI 10.2337/dc14-2441.
25. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5):1083-1091 DOI 10.2337/diacare.28.5.1083.
26. Liu SC, Chien KL, Wang CH, ChenWC, Leung CH. 2013. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocrine Practice 19(6):980-988 DOI 10.4158/EP13148.OR.
27. Lukashevich V, Prato SD, Araga M, Kothny W. 2014. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, Obesity and Metabolism 16(5):403-409 DOI 10.1111/dom.12229.
28. Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 151(4):264-269 DOI 10.7326/0003-4819-151-4-200908180-00135.
29. Monami M, Iacomelli I, Marchionni N, Mannucci E. 2010. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 20(4):224-235 DOI 10.1016/j.numecd.2009.03.015.
30. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA. 2014. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes, Obesity and Metabolism 16(5):443-450 DOI 10.1111/dom.12234.
31. National Institute for Health and Clinical Excellence. 2011. Type 2 diabetes: newer agents. In: Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: National Institute for Health and Clinical Excellence. Available at https://www.nice.org.uk/guidance/cg87 (accessed 29 November 2015).
32. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. 2007. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50(2):259-267 DOI 10.1007/s00125-006-0510-2.
33. New Zealand Guidelines Group. 2011. Guidance on the Management of type 2 diabetes 2011. Wellington: New Zealand Guidelines Group. Available at https://www1.accu-chek.co.nz/documents/AccuChekExtra/NZGG-management-of-type-2-diabetes-web-v2.pdf (accessed 29 November 2015).
34. Norris SL, Carson S, Roberts C. 2007. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Current Diabetes Reviews 3(2):127-140 DOI 10.2174/157339907780598216.
35. Owens DR, Swallow R, Dugi KA, Woerle HJ. 2011. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabetic Medicine 28(11):1352-1361 [Erratum appears in Diabet Med. 2012 Jan;29(1):158] DOI 10.1111/j.1464-5491.2011.03387.x.
36. Rigato M, Fadini GP. 2014. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7:107-120 DOI 10.2147/DMSO.S37644.
37. Rodbard H, Jellinger P, Davidson J, Einhorn D, Garber A, Grunberger G, Handelsman Y, Horton E, Lebovitz H, Levy P, Moghissi E, Schwartz S. 2009. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 15(6):540-559 DOI 10.4158/EP.15.6.540.
38. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. 2006. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29(3):554-559 DOI 10.2337/diacare.29.03.06.dc05-0695.
39. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E. 2009. Action in diabetes 5 met SUSG. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52(10):2046-2055 DOI 10.1007/s00125-009-1472-y.
40. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G. 2013. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36(9):2508-2515 DOI 10.2337/dc12-2491.
41. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelova A, Thomsen HF, Kalra S. 2009. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Current Medical Research and Opinion 25(12):2887-2894 DOI 10.1185/03007990903354674.
42. White IR. 2011. Multivariate random-effects meta-regression: updates to mvmeta. Stata Journal 11(2):255-270.
43. WHO. 2013. Mortality and global health estimates. Geneva: World Health Organization. Available at http://www.who.int/gho/mortalityburdendisease/en/(accessed 20 January 2015).
44. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. 2013. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International Journal of Clinical Practice 67(12):1267-1282 DOI 10.1111/ijcp.12322.
45. Yang W, Xu X, Liu X, Yang G, Seino Y, Andersen H, Jinnouchi H. 2013. Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes. Current Medical Research and Opinion 29(12):1599-1608 DOI 10.1185/03007995.2013.838155.